Intraperitoneal insulin infusion: treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Continuous intraperitoneal insulin infusion (CIPII) is a treatment option for patients with type 1 diabetes mellitus who fail to reach adequate glycaemic control despite intensive subcutaneous (SC) insulin therapy. CIPII has clear advantages over SC insulin administration in terms of pharmacokinetic and pharmacodynamic properties and has been shown to improve glycaemic regulation. Due to the delivery of insulin predominantly in the portal vein, as opposed to systemically, CIPII offers a unique research model to investigate the effects of insulin on endocrine and metabolic parameters in vivo. The aim of the present article is to provide an overview of the literature with respect to the effects of CIPII on glucose management, quality of life, complications and costs, with additional focus on metabolic and endocrine aspects. Finally, future use and research objectives are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artificial Pancreas: Past, Present, Future
Cobelli, C., Renard, E., & Kovatchev, B. (2011) · Diabetes · doi:10.2337/db11-0654 · Cited by 600
Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review
DeWitt, D. E., & Hirsch, I. B. (2003) · JAMA · doi:10.1001/jama.289.17.2254 · Cited by 502
Cox, D. J., Kovatchev, B. P., Julian, D. M., Gonder-Frederick, L. A., Polonsky, W. H., Schlundt, D. G., & Clarke, W. L. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989471 · Cited by 137
Burnett, D. R., Huyett, L. M., Zisser, H. C., Doyle, F. J., & Mensh, B. D. (2014) · Diabetes · doi:10.2337/db13-1649 · Cited by 52
Cited by
Dassau, E., Renard, E., Place, J., Farret, A., Pelletier, M., Lee, J., Huyett, L. M., Chakrabarty, A., Doyle, F. J., & Zisser, H. C. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12999 · Cited by 94
“There is some evidence to show that this difference results in better insulin/glucagon balance and glycaemic variability.(13,14) Some recent studies(15,16) indicate that prolonged use of IP infusion does not adversely affect insulin-like growth-factor-1 (IGF-1) concentrations, as observed with prolonged SC use.”
BackgroundThe Peripheral Peril: Injected Insulin Induces Insulin Insensitivity in Type 1 Diabetes
Gregory, J. M., Cherrington, A. D., & Moore, D. J. (2020) · Diabetes · doi:10.2337/dbi19-0026 · Cited by 76
Modeling Intraperitoneal Insulin Absorption in Patients with Type 1 Diabetes
Schiavon, M., Cobelli, C., & Dalla Man, C. (2021) · Metabolites · doi:10.3390/metabo11090600 · Cited by 6
“To partially overcome these issues, the intraperitoneal (IP) route of administration can be used [4].”
Background
Metadata
- Authors
- van Dijk, P. R., Logtenberg, S. J. J., Gans, R. O. B., Bilo, H. J. G., & Kleefstra, N.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2014-07-28
- Volume
- 81
- Issue
- 4
- Pages
- 488-497
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2069680099
- Cited by
- 44
- References
- 4
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.